For localised injection site reactions , several practical measures can provide relief: Rotate injection sites within the abdomen, thigh, and upper arm, following the technique taught by your healthcare professional Ensure proper injection technique as described in the Patient Information Leaflet Apply a cool compress to the injection site if mild swelling or discomfort occurs Avoid injecting into areas with scarring, bruising, or skin changes Consider whether other factors such as alcohol swabs or adhesives might be causing local irritation For mild generalised rash or itching , your GP may recommend: Oral antihistamines (such as cetirizine or loratadine) to reduce itching and allergic response Emollients and moisturisers applied regularly to maintain skin barrier function Topical corticosteroids of appropriate potency for short courses on affected areas (avoiding face and flexures unless specifically directed) Avoidance of potential irritants including harsh soaps, fragranced products, and excessive heat If skin reactions are confirmed to be related to Ozempic and are causing significant problems, your diabetes specialist may consider dose adjustment or temporary treatment interruption to allow resolution
10.1001/archinte.161.13.1581 43 FruhbeckG
This is one of the reasons the field has paid such close attention to cysteine pools across decades of research
Qu HM, Liu SJ, Zhang CY
A Google Trends analysis published in the Aesthetic Surgery Journal, 2023 found that public search interest in Ozempic grew exponentially between 2018 and 2023, consistently outpacing search interest in Wegovy and Mounjaro during the same window a clear signal that public curiosity was running well ahead of medical need
Per publicly available FDA and manufacturer announcements, the Wegovy pill (once-daily oral semaglutide 25mg) received FDA approval on December 22, 2025 and launched broadly across US pharmacies in January 2026 - the first oral GLP-1 receptor agonist approved for chronic weight management
